Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GLP-1 receptor agonists, cancer risk and questionable significance

2.

Benefits of perioperative radiotherapy for liver cancer with a high risk of recurrence are investigated in research.

3.

Pancreatic cancer RNA vaccine shows durable T cell immunity

4.

Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer

5.

Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot